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Hirudin elimination by hemofiltration: A comparative in vitro duced for the prophylaxis of thromboembolism after hip
study of different membranes. replacement [1]. Further applications such as treatment
Background. Recombinant hirudin (r-hirudin) is a highly of thromboembolism [2], acute coronary syndromesspecific and selective thrombin inhibitor. Since 1997, it has
[3, 4], sepsis and disseminated intravascular coagulationbeen approved for the treatment of heparin-induced thrombo-
cytopenia (HIT type II). Renal function impairment drastically (DIC) [5], and chronic renal replacement therapy [6, 7],
prolongs the elimination half-life time. In cases of bleeding or are under investigation.
overdosage, there is currently no antidote available. Hemofil- In clinical studies with selected patient populations,tration has been reported to be useful in r-hirudin elimination.
r-hirudin has been shown to be an effective and safeIn this study, we determined sieving coefficients (SCs) and
drug clearances for two different hemofilters currently used in anticoagulant. It works as a highly specific and selective
clinical medicine and intensive care. thrombin inhibitor forming tight stoichiometric com-
Methods. We developed an in vitro postdilution hemofiltra- plexes independent from cofactors like antithrombin [8].
tion model using 500 ml heparinized (2 IU unfractionated hepa-
It is a small single-chain polypeptide consisting of 65rin/ml) fresh human blood and bicarbonate substitution fluid.
amino acids (molecular weight 6980 Da) that rapidlyThe investigated membranes were high-flux polysulfone F50
(1.0 m2, Fresenius) and AN69 Nephral 200 (1.05 m2, Hospal distributes to the extracellular space (t1/2 a 0.1 to 0.35
Cobe). After equilibration, a bolus of Lepirudin was injected hr) showing no relevant protein binding. As r-hirudin is
into the postfilter port to achieve a r-hirudin blood level of
almost exclusively excreted in unchanged form via theapproximately 15 mg/ml. Serial blood and ultrafiltrate samples
kidneys, impairment of renal function drastically in-were taken for the determination of hirudin levels (chromo-
genic assay) and control parameters. SC and clearances were creases the elimination half-life time (t1/2 b). In healthy
calculated according to standard formulae. volunteers, r-hirudin disappears with a t1/2 b of one to
Results. The observed SCs and clearances differed signifi- two hours, which is comparable with unfractionated hep-cantly between F50 and Nephral 200 (0.60 6 0.17 and 21.0 6
arin. In chronic hemodialysis patients, elimination half-5.9 ml/min, respectively, vs. 0.44 6 0.09 and 15.5 6 3.0 ml/min,
life time is prolonged by a factor 30 to 40 (t1/2 b 36 to 75respectively; P 5 0.001). The determination of prothrombin
fragments showed no coagulation activation during the experi- hr). After bilateral nephrectomy, elimination is further
ments. The hematocrit values remained stable. delayed (t1/2 b 160 to 320 hr) [9–11]. In cases of overdos-Conclusions. Our data show that r-hirudin can be eliminated
age, the clinical situation is complicated by the fact thatby hemofiltration. The elimination obviously depends on the
there is presently no antidote available. Thus, seriousmembrane material with high-flux polysulfone being more ef-
fective than AN69. These findings may be important in cases bleeding complications may result. In single patients,
of overdosage and for r-hirudin dosage guidelines in continuous hemofiltration has been reported to be useful for r-hiru-
hemofiltration. din elimination [12]. Experimental and clinical data on
the permeability of membranes used in renal replace-
ment therapy are rare and inconclusive [11, 13–15].
Since 1997, the recombinant hirudin (r-hirudin) lepiru- On this background, we decided to perform a compar-
din has been approved for the treatment of the immuno- ative in vitro study in order to determine sieving coeffi-
logical form of heparin-induced thrombocytopenia (HIT
cients (SCs) and drug clearances for two different mem-
type II). Another r-hirudin, Desirudin, has been intro-
brane materials currently used in intermittent and
continuous hemofiltration. In order to simulate clinically
relevant conditions, we used heparinized fresh humanKey words: membrane biocompatibility, sieving coefficient, dialysis
membrane, hemofilter. blood in a hemofiltration model without ultrafiltrate re-
infusion. 1999 by the International Society of Nephrology
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Fig. 1. Schematic drawing of the in vitro hemofil-
tration model.
METHODS recirculated with a flow rate of 110 ml/min via a peristal-
tic pump passing through an adult-size hemofilter. TheMaterials
ultrafiltrate was collected and completely replaced withThe investigated hollow fiber hemofilters were high-
a bicarbonate substitution fluid (SH43-HEP) supple-flux polysulfone F50 (surface area 1 m2, blood compart-
mented with 4 mval/liter potassium. The flow rate wasment 63 ml, ultrafiltrate compartment 84 ml; Fresenius
adjusted via a second peristaltic pump according to theMedical Care, Bad Homburg, Germany) and AN69
ultrafiltrate flow rate to avoid hemoconcentration. Sam-Nephral 200 (1.05 m2, 64 ml and 41 ml; Hospal Cobe,
ples for laboratory analysis were taken from prefilterLyon, France). The r-hirudin lepirudin (Refludant) was
and postfilter ports (P1 and P2) together with ultrafiltratefrom Hoechst Marion Roussel (Frankfurt, Germany).
Ecarin was obtained from Pentapharm Ltd. (Basel, Swit- samples from port 3 (P3).
zerland). The bicarbonate substitution fluid SH43-HEP
and isotonic saline were supplied from B. Braun Schiwa Experimental procedure
(Glandorf, Germany). The blood transfer bags used as Prior to the experiments, the system was prefilled and
a reservoir were purchased from Biotrans (Dreieich, rinsed with 2 liters of isotonic saline. After rinsing, the
Germany). Meise Medizintechnik (Schalksmu¨hle, Ger- saline was carefully replaced with the 500 ml of human
many) manufactured the specially adapted single-use
blood, and the circulation was started. To allow equili-
tubing systems. We performed the experiments with the
bration of the system and formation of a membraneHospal BSM22 SC.
protein layer, hemofiltration was commenced without
Blood collection lepirudin. After 10 minutes, ultrafiltration and substitu-
tion were temporarily stopped. Then a bolus of r-hirudinBlood was collected from healthy volunteers [36 6 17
(lepirudin) was injected into the postfilter port. Afteryears (mean 6 sd), range 18 to 64 years], denying any
five minutes of recirculation, filtration and substitutionmedication with known influence on platelets or coagula-
tion. After a clean puncture of a forearm vein, a plastic were restarted, and the first blood sample was taken (0
cannula was carefully inserted. The first five milliliters min). Further blood sampling was done every five min-
of blood were discarded to avoid artificial coagulation utes for the next 45 minutes from the prefilter and post-
activation. Then 450 ml of whole blood were collected filter port. To allow for progress through the ultrafiltrate
in a prepared blood transfer bag containing 50 ml of a compartment and tubing, ultrafiltrate samples were
sodium heparin solution (unfractionated porcine hepa- taken 70 to 150 seconds later than the related blood
rin), achieving a final heparin concentration of 2 IU per
samples, depending on the filtrate compartment volumeml. Within 30 minutes after the blood collection, the
of the hemofilter. At the end of the experiments, the sys-hemofiltration experiments were started.
tem was rinsed again with isotonic saline until the blood-
Hemofiltration model conducting system appeared macroscopically clean. The
hemofilters were checked for clotting. Control experi-The in vitro hemofiltration was conducted in the post-
ments were performed by omitting ultrafiltration anddilution mode using the experimental set-up shown in
Figure 1. The heparinized fresh human whole blood was fluid substitution after the addition of r-hirudin.
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Table 1. Formulae used for the calculationsSample processing
Blood samples were taken into microtubes (Sarstedt, Sieving coefficient 5 2 Cu
Cwi 1 CwoNu¨mbrecht, Germany) containing 1/10 volume 0.106 m
trisodium citrate for the coagulation assays or potassium
Cw 5
Plasma drug concentration
1 2 (Total protein concentration 3 0.0107)ethylenediaminetetraacetic acid (EDTA) for the com-
plete blood count. Ultrafiltrate samples were collected
Clearance 5
Cu 3 UFR
Cwi
into microtubes (Eppendorf Reagiergefa¨be 1.5 ml). Ci-
trated platelet poor plasma was obtained by centrifuga-
tion (2000 g, 10 min). Plasma and ultrafiltrate samples Abbreviations are: Cwi, prefilter plasma-water drug concentration; Cwo, post-
filter plasma-water drug concentration; Cu, ultrafiltrate drug concentration; Cw,were stored in aliquots deep frozen at 2708C until analy-
plasma-water drug concentration; UFR, ultrafiltrate flow rate.
sis. For monitoring the acid-base status and lactate and
electrolyte levels, blood was collected into self-filling
heparinized syringes (Picot70; Radiometer Medical, Co-
penhagen, Denmark), stored at 48C and measured within ing significant differences. The calculations of SCs and
one hour. clearances are based on 16 independent experiments,
including three control experiments (N 5 8 each for F50
Laboratory analysis and Nephral) with 27 and 21 single values, respectively.
Hirudin levels in plasma were assayed using a commer-
cially available chromogenic test kit (Hirudin-Test; Dade
RESULTSBehring, Marburg, Germany), which measures the func-
tionally active free hirudin. As a control, plasma hirudin Figure 2 depicts the decline of the prefilter plasma r-
levels were also measured with a coagulometric assay hirudin level over the time (mean 6 sd) for F50 and
[ecarin clotting time (ECT)] [16]. Lyophilized Ecarin (50 Nephral 200. At the beginning, the hirudin levels were
U per vial) was reconstituted in HEPES buffer, pH 7.4, similar (14.6 6 1.4 vs. 13.8 6 3.7 mg/ml, P 5 NS). After
containing 0.025 m calcium chloride. An Ecarin concen- 5, 10, 15, and 20 minutes, the r-hirudin levels were sig-
tration of 2.5 U/ml was found to be optimal for this nificantly lower with F50 than with Nephral (P , 0.05).
application. One hundred microliters of Ecarin solution The calculated SCs and hirudin clearances for F50 were
were added to 200 ml of undiluted citrate-anticoagulated 0.60 6 0.17 resp. 21.0 6 5.9 ml/min and for Nephral 200
plasma. The time until clotting was registered on a KC were 0.44 6 0.09 resp. 15.5 6 3.0 ml/min. The differences
10 coagulometer. ECT was shown to be unaffected by were statistically significant (P , 0.01). During the con-
heparin. trol experiments omitting ultrafiltration, the r-hirudin
Prothrombin fragments 1 and 2 (F112) were deter- levels did not decline, excluding that relevant quantities
mined in blood and ultrafiltrate samples with the ELISA of r-hirudin were adsorbed to the circuit surfaces. The
Enzygnoste F112 micro test kit (Dade Behring) in order achieved ultrafiltrate flow rates were identical for F50
to detect coagulation activation caused by the extracor- and Nephral 200 (35.2 6 1.2 vs. 35.5 6 1.0 ml/min) and
poreal circulation, which could lead to hirudin consump- remained stable during the course of the experiments.
tion. Also, the values for pH, lactate, and bicarbonate were
Blood cell count was performed automatically using comparable (at 30 min, pH 7.31 6 0.03 vs. 7.35 6 0.04,
the Serono System 9000 Hematology Cell Counter (Bio- P 5 NS; 2.61 6 0.1 vs. 2.66 6 0.1 mmol/liter, P 5 NS;
Chem ImmunoSystems, Freiburg, Germany). Blood acid- 36.3 6 2.9 vs. 38.5 6 5.0 mmol/liter, P 5 NS). Sodium
base status, lactate, and electrolyte levels were analyzed and potassium were within the normal range. The cal-
on the ABL System 610 (Radiometer, Copenhagen, cium levels were slightly increased, caused by the substi-
Denmark). tution fluid containing 1.83 mmol/liter Ca21.
The prothrombin fragments 1 1 2 (F112) as a marker
Calculations for thrombin generation remained constant in the blood
Plasma water drug concentrations, SCs, and drug compartment. To exclude F112 elimination via hemofil-
clearances were calculated using standard formulae as tration, we repeatedly analyzed ultrafiltrate samples with
shown in Table 1. no relevant F112 levels detectable. Thus, there was no
significant coagulation activation during the extracorpo-
Statistical analysis real circulation. Moreover, the F112 levels did not differ
between the two hemofilters. The hematocrit as a markerAll results are expressed as mean values 6 sd. The
data were statistically analyzed using SPSS 7.5 for Win- of the fluid balance remained stable, indicating that no
hemoconcentration or dilution affecting the hirudin lev-dows and the nonparametric Mann–Whitney rank sum
test. A P value of less than 0.05 was considered as indicat- els occurred during the experiments.
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Fig. 2. Time course of the prefilter recombinant
(r)-hirudin levels during in vitro hemofiltration.
Starting from the same level at t 5 0 min, the r-
hirudin level (mean 6 sd) declined more rapidly
with F50 ( ) compared with Nephral 200 (j).
The differences were statistically significant at time
points 5, 10, 15, and 20 minutes (P , 0.05). The
control experiments (lines) showed unchanged r-
hirudin levels [(h) F50, (r) Nephral 200].
DISCUSSION results, membrane-specific differences exist regarding
hirudin permeability.Recombinant hirudin is increasingly applied in clinical
Drug removal with hemofiltration is determined bymedicine as an alternative anticoagulant to heparin. Acci-
drug as well as membrane properties. Protein binding,dental overdosage or unexpected accumulation of r-hiru-
molecular weight and molecular charge of the drug, poredin in patients with renal insufficiency may cause severe
size and membrane charge are the main influencing fac-bleeding complications. Because there is no antidote,
tors. The percentage of protein binding is regarded aselimination via hemofiltration has been recommended
the primary variable limiting drug sieving. The removalfor these situations [12]. Despite this, detailed informa-
of drugs bound to plasma proteins (.10%) was substan-tion about the hirudin permeability (SC) of the different
tially increased in hemofiltration experiments with salinecurrently used membranes for intermittent or continuous
[17]. Plasma proteins may form a protein layer (secondhemofiltration is not available in the literature. From
membrane) functioning as a physical barrier, which canits pharmacokinetic features, r-hirudin seems to be a
significantly modify the membrane permeability. Thus,suitable substance for elimination via hemofiltration, as
the experimental conditions obviously seem to play ait is a relatively small molecule (6890 Da) and shows no
crucial role and have to be chosen carefully.
relevant protein binding [8]. However, experimental and
With our model, we attempted to mimic clinical hemo-
clinical findings are inconclusive. Bucha, Markwardt, and filtration by using heparin-anticoagulated fresh human
Nowak performed experiments with nephrectomized whole blood, in order to maintain blood pH values,
dogs, showing that hemodialysis with high-flux polysul- plasma protein concentrations, and electrolyte levels
fone or AN69 in contrast to low-flux dialysis led to a close to the physiological range in the human body. This
rapid decline of the blood hirudin levels within minutes approach should minimize artificial changes of molecular
[13]. An animal study with minipigs gives further evi- charge, hydration, and protein binding characteristics,
dence that high-flux membranes are effective in hirudin which may influence the drug–membrane interaction and
elimination [14]. Furthermore, Nowak et al report from facilitate extrapolation to the in vivo situation. Our goal
in vitro dialysis studies with bovine blood that hemophan was to determine SCs and clearances of r-hirudin for
is also highly permeable for r-hirudin, despite being clas- two widely used membranes that have different physico-
sified as low-flux membrane [15]. In contrast to these chemical properties.
findings, Vanholder et al conclude that clinical high-flux In the setting of the described in vitro hemofiltration
polysulfone hemodialysis with ultrafiltration does not model, high-flux polysulfone (F50) appeared to be supe-
contribute to r-hirudin elimination from the circulation rior to AN69 (Nephral 200; P , 0.01). The control pa-
in humans. Additionally, they describe in vitro experi- rameters (acid-base status, hematocrit, and electrolytes)
ments demonstrating r-hirudin as being unable to pass were not significantly different, indicating that the exper-
through high-flux polysulfone membranes [11]. imental conditions were similar for F50 and Nephral 200.
The results of our in vitro study clearly demonstrate The calculated SCs and clearances do not indicate a free
that r-hirudin (lepirudin) can permeate through polysul- passage through the investigated membranes. AN69 as
a more negatively charged membrane, compared withfone and AN69 high-flux hemofilters. According to our
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